Life Sciences Times, Author at Boston Life Sciences Times

Casma Therapeutics Secures $7.6 Million in MJFF Funding to Advance Parkinson’s Disease Program

March 10, 2026

NEJM Publishes Data Suggesting Zorevunersen May Modify Disease Course in Dravet Syndrome

March 5, 2026

Arsenal Medical Treats First Patient with ResQFoam Device for Life-Threatening Abdominal Bleeding

March 4, 2026

THIS WEEK'S STORIES

FDA Grants Priority Review to ENHERTU for High-Risk HER2-Positive Early Breast Cancer

March 9, 2026

UK Biotech Firm Abselion Opens U.S. Subsidiary in Cambridge Innovation Hub

March 9, 2026

Newton Women’s Health Company Reports Study Showing Leva Device Improves Fecal Incontinence Symptoms

March 9, 2026

ABOUT US

Life Science Times is New England’s premier life sciences publication, covering the Pharma, Biotech, MedTech and Public Health sectors nationwide with a special focus on New England. Updated daily, we cover the latest news in everything else that touches any rubric of the rapidly growing life sciences industry.

Life Sciences Times

TOP AUTHORS

Most Read

Aurion Biotech Names Marjan Farid, M.D., Chair of Medical Advisory Board

Parabilis Medicines’ Zolucatetide Receives FDA Orphan Drug Designation for Desmoid Tumors

GelMEDIX, Catalent Partner to Develop Stem Cell-Based Therapies for Ocular and Retinal Diseases

Cognito Therapeutics Names Thomas Fagan Executive Vice President of Alzheimer’s Portfolio

EDITOR PICKS

Casma Therapeutics Secures $7.6 Million in MJFF Funding to Advance Parkinson’s Disease Program

NEJM Publishes Data Suggesting Zorevunersen May Modify Disease Course in Dravet Syndrome

Arsenal Medical Treats First Patient with ResQFoam Device for Life-Threatening Abdominal Bleeding

THIS WEEK'S STORIES

FDA Grants Priority Review to ENHERTU for High-Risk HER2-Positive Early Breast Cancer

UK Biotech Firm Abselion Opens U.S. Subsidiary in Cambridge Innovation Hub

Newton Women’s Health Company Reports Study Showing Leva Device Improves Fecal Incontinence Symptoms

POPULAR CATEGORY

ABOUT US

FOLLOW US